Biomarkers /
MET
Back to Biomarkers List
Overview
MET (MET proto-oncogene, receptor tyrosine kinase) encodes the hepatocyte growth factor receptor protein. Germline mutations in the tyrosine kinase domain of MET occur in 100% of hereditary papillary renal cell carcinoma (PMID: 9140397). Somatic MET mutations and/or amplifications have been observed in sporadic papillary renal cell carcinoma, head and neck squamous cell carcinoma (PMID: 10734314), childhood hepatocellular carcinoma (PMID: 9927037), lung cancer (PMID: 14559814; PMID: 17463250), gastric cancer (PMID: 10223227), esophageal cancer (PMID: 16186806), colorectal cancer (PMID: 10343196), gliomas (PMID: 18077431), and clear cell ovarian cancer (PMID: 21478826). In the context of malignancy, aberrant signaling through the MET receptor promotes pleiotrophic effects including growth, survival, invasion, migration, angiogenesis and metastasis (Birchmeier et al. 2003; Peruzzi and Bottaro 2006).
Biomarker-Directed Therapies
MET is a predictive biomarker for use of capmatinib, crizotinib, afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cemiplimab, pembrolizumab, and tepotinib in patients.
Non-small cell lung carcinoma has the most therapies with MET as a predictive biomarker.
Of the therapies with MET as a predictive biomarker, 4 are FDA-approved in at least one clinical setting and 9 have NCCN guidelines in at least one clinical setting.
MET Amplification and MET Exon 14 Skipping are the top alterations on MET targeted by therapies [4].
Afatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Capmatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for adult patients with metastatic non-small cell lung cancer with a mutation that leads to MET exon 14 skipping. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended by NCCN for patients with high-level MET amplification. |
Crizotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended by NCCN under Category 2A for patients with high-level MET amplification or MET exon 14 skipping mutations. |
Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Pembrolizumab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with a ROS1, RET, BRAF V600E, or MET Exon 14 Skipping alteration: approved as a single agent for first- or subsequent-line therapy. However, per NCCN, targeted therapy for the oncogenic driver should take precedence over an immune checkpoint inhibitor. |
Tepotinib +
Non-Small Cell Lung Carcinoma -
Afatinib + Capmatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Afatinib + Crizotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Clinical Trials
MET status serves as an inclusion eligibility criteria in 91 clinical trials, of which 54 are open and 37 are closed. Of the trials that contain MET status as an inclusion criterion, 3 are early phase 1 (1 open), 29 are phase 1 (13 open), 10 are phase 1/phase 2 (5 open), 44 are phase 2 (32 open), 4 are phase 3 (2 open), and 1 is no phase specified (1 open).
Trials with MET status in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma, malignant solid tumor, breast carcinoma, non-squamous non-small cell lung carcinoma, and adenocarcinoma of the gastroesophageal junction [4].
The most frequent alterations to serve as inclusion eligibility criteria are MET Amplification, MET Overexpression, MET Exon 14 Skipping, MET Mutation, and MET Fusion [4].
Crizotinib, capmatinib, savolitinib, cabozantinib, and placebo are the most frequent therapies in trials with MET as an inclusion criteria [4].
Significance of MET in Diseases
Non-Small Cell Lung Carcinoma +
MET is an inclusion criterion in 42 clinical trials for non-small cell lung carcinoma, of which 29 are open and 13 are closed. Of the trials that contain MET status and non-small cell lung carcinoma as inclusion criteria, 12 are phase 1 (7 open), 5 are phase 1/phase 2 (4 open), 23 are phase 2 (17 open), and 2 are phase 3 (1 open) [4].
Capmatinib, afatinib, crizotinib, dacomitinib, erlotinib, gefitinib, osimertinib, pembrolizumab, and tepotinib have evidence of efficacy in patients with MET mutation in non-small cell lung carcinoma [4].
Malignant Solid Tumor +
MET is an inclusion criterion in 28 clinical trials for malignant solid tumor, of which 15 are open and 13 are closed. Of the trials that contain MET status and malignant solid tumor as inclusion criteria, 14 are phase 1 (5 open), 6 are phase 1/phase 2 (3 open), and 8 are phase 2 (7 open) [4].
Adenocarcinoma Of The Gastroesophageal Junction +
MET is an inclusion criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 5 are open and 3 are closed. Of the trials that contain MET status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), and 4 are phase 2 (2 open) [4].
Breast Carcinoma +
MET is an inclusion criterion in 8 clinical trials for breast carcinoma, of which 4 are open and 4 are closed. Of the trials that contain MET status and breast carcinoma as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (3 open) [4].
Colorectal Carcinoma +
MET is an inclusion criterion in 8 clinical trials for colorectal carcinoma, of which 4 are open and 4 are closed. Of the trials that contain MET status and colorectal carcinoma as inclusion criteria, 6 are phase 1 (2 open) and 2 are phase 2 (2 open) [4].
Gastric Adenocarcinoma +
MET is an inclusion criterion in 7 clinical trials for gastric adenocarcinoma, of which 4 are open and 3 are closed. Of the trials that contain MET status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 4 are phase 2 (2 open) [4].
Hepatocellular Carcinoma +
MET is an inclusion criterion in 7 clinical trials for hepatocellular carcinoma, of which 6 are open and 1 is closed. Of the trials that contain MET status and hepatocellular carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (3 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [4].
Melanoma +
MET is an inclusion criterion in 6 clinical trials for melanoma, of which 3 are open and 3 are closed. Of the trials that contain MET status and melanoma as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (1 open), and 3 are phase 2 (2 open) [4].
Cancer +
MET is an inclusion criterion in 4 clinical trials for cancer, of which 2 are open and 2 are closed. Of the trials that contain MET status and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 3 are phase 1 (2 open) [4].
Gastric Carcinoma +
MET is an inclusion criterion in 4 clinical trials for gastric carcinoma, of which 2 are open and 2 are closed. Of the trials that contain MET status and gastric carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (0 open) [4].
Squamous Cell Lung Carcinoma +
MET is an inclusion criterion in 4 clinical trials for squamous cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain MET status and squamous cell lung carcinoma as inclusion criteria, 3 are phase 2 (3 open) and 1 is no phase specified (1 open) [4].
Bladder Carcinoma +
MET is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MET status and bladder carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Glioblastoma +
MET is an inclusion criterion in 3 clinical trials for glioblastoma, of which 1 is open and 2 are closed. Of the trials that contain MET status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].
Head And Neck Carcinoma +
MET is an inclusion criterion in 3 clinical trials for head and neck carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MET status and head and neck carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Head And Neck Squamous Cell Carcinoma +
MET is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MET status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Lymphoma +
MET is an inclusion criterion in 3 clinical trials for lymphoma, of which 1 is open and 2 are closed. Of the trials that contain MET status and lymphoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [4].
Prostate Carcinoma +
MET is an inclusion criterion in 3 clinical trials for prostate carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MET status and prostate carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].
Colorectal Adenocarcinoma +
MET is an inclusion criterion in 2 clinical trials for colorectal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [4].
Endometrial Carcinoma +
MET is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].
Multiple Myeloma +
MET is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain MET status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [4].
Ovarian Carcinoma +
MET is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].
Pancreatic Adenocarcinoma +
MET is an inclusion criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [4].
Pancreatic Carcinoma +
MET is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].
Renal Cell Carcinoma +
MET is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MET status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Soft Tissue Sarcoma +
MET is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain MET status and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Urothelial Carcinoma +
MET is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [4].
Adrenal Cortex Carcinoma +
MET is an inclusion criterion in 1 clinical trial for adrenal cortex carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and adrenal cortex carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Alveolar Soft Part Sarcoma +
MET is an inclusion criterion in 1 clinical trial for alveolar soft part sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and alveolar soft part sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Anaplastic Astrocytoma +
MET is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains MET status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].
B-Cell Non-Hodgkin Lymphoma +
MET is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Bile Duct Carcinoma +
MET is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Bronchogenic Carcinoma +
MET is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Cervical Carcinoma +
MET is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Cervical Squamous Cell Carcinoma +
MET is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Cholangiocarcinoma +
MET is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Clear Cell Renal Cell Carcinoma +
MET is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Clear Cell Sarcoma Of Soft Tissue +
MET is an inclusion criterion in 1 clinical trial for clear cell sarcoma of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains MET status and clear cell sarcoma of soft tissue as inclusion criteria, 1 is phase 2 (1 open) [4].
Diffuse Intrinsic Pontine Glioma +
MET is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains MET status and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Esophageal Carcinoma +
MET is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MET status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Esophageal Squamous Cell Carcinoma +
MET is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ewing Sarcoma +
MET is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and Ewing sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Gallbladder Carcinoma +
MET is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Glioma +
MET is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains MET status and glioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Gliosarcoma +
MET is an inclusion criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Hepatoblastoma +
MET is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and hepatoblastoma as inclusion criteria, 1 is phase 2 (1 open) [4].
High Grade Ovarian Serous Adenocarcinoma +
MET is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Lung Adenocarcinoma +
MET is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Lung Carcinoma +
MET is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Uterine Neoplasm +
MET is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MET status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Medulloblastoma +
MET is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Mesothelioma +
MET is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains MET status and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Mucosal Melanoma +
MET is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Non-Squamous Non-Small Cell Lung Carcinoma +
MET is an inclusion criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Osteosarcoma +
MET is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Papillary Renal Cell Carcinoma +
MET is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].
Rhabdomyosarcoma +
MET is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and rhabdomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Sarcoma +
MET is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MET status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Small Intestinal Adenocarcinoma +
MET is an inclusion criterion in 1 clinical trial for small intestinal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MET status and small intestinal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Thyroid Gland Medullary Carcinoma +
MET is an inclusion criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Wilms Tumor +
MET is an inclusion criterion in 1 clinical trial for Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains MET status and Wilms tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
